SecBot SecBot
Biotech Drug Report Generated Nov 7, 2026

remlifanserin

ACAD·ACADIA PHARMACEUTICALS INC
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 3
Time to market
The Phase 3 RADIANT program's estimated primary completion is January 2028 per ClinicalTrials.gov. If Phase 3 succeeds, an NDA submission would follow, putting a potential FDA decision no earlier than late 2028 or 2029.
Why 4/10
The next hard catalyst is the CTAD conference presentation (November 16-19, 2026), but this is a detailed data disclosure, not a binary regulatory/pivotal readout. The Phase 3 RADIANT program's estimated primary completion is January 2028, more than 12 months away, so no near-term binary catalyst exists. Acadia has two approved, revenue-generating products (Nuplazid and Daybue, $342M/quarter), so remlifanserin is a major pipeline asset but not the sole driver of company value. Impact score is 4.
Actionable Insight NEUTRAL

Watch the CTAD conference (November 16-19, 2026) for detailed Phase 2 data that could shift sentiment. The key binary catalyst is the Phase 3 RADIANT readout, estimated for January 2028. In the interim, Acadia's quarterly earnings and commercial execution of Nuplazid/Daybue will likely drive the stock more than remlifanserin news. A Phase 3 success could open a multi-billion-dollar ADP market; a failure would remove a key pipeline asset but leave Acadia's approved-product revenue intact.

Price Chart

Loading chart...

Executive Summary

Remlifanserin (ACP-204) is Acadia Pharmaceuticals' next-generation 5-HT2A receptor inverse agonist in Phase 3 for Alzheimer's disease psychosis, a condition with no approved therapies. The Phase 2 RADIANT study narrowly missed its primary endpoint (p=0.0603) but showed consistent efficacy signals at the 60 mg dose, leading Acadia to continue Phase 3 with a refined design. The drug also has Fast Track designation from the FDA. With Phase 3 data not expected until early 2028, remlifanserin is a mid-to-long-term pipeline value driver for Acadia, which already generates over $1.3B in annual revenue from Nuplazid and Daybue. The stock trades at $21.23, well below the $30.53 mean analyst target, reflecting uncertainty around the Phase 3 program after the near-miss.

How It Works

Remlifanserin is a small-molecule pill that blocks a specific serotonin receptor (5-HT2A) in the brain. By dampening overactivity at this receptor, it aims to reduce hallucinations and delusions without the motor side effects typical of older antipsychotics. It is a next-generation follow-on to Acadia's approved drug pimavanserin (Nuplazid), designed to be more potent and selective and to avoid the heart-rhythm risk (QT prolongation) that limited pimavanserin.

Trial Status

Remlifanserin is being studied under the RADIANT master protocol (NCT06159673), an operationally seamless Phase 2/3 program in Alzheimer's disease psychosis (ADP). The Phase 2 portion (approx. 318 patients) tested 30 mg and 60 mg once-daily doses vs placebo over 6 weeks. Topline results reported September 24, 2026: the 60 mg dose narrowly missed the primary endpoint (SAPS-H+D, p=0.0603) but hit a key secondary endpoint with nominal significance (CGI-S-ADP, p=0.0077). The 30 mg arm showed minimal benefit. Acadia is continuing two ongoing Phase 3 substudies with only the 60 mg dose and plans to enroll patients with more severe psychosis. A separate Phase 2 trial in Lewy body dementia psychosis (NCT07029581) is also recruiting.

The Two-Sided Case

▲ Bull Case5
Remlifanserin targets a large unmet need: there are no FDA-approved treatments specifically for Alzheimer's disease psychosis, which affects an estimated 30-50% of Alzheimer's patients.
The Phase 2 data showed a clear dose-response with consistent efficacy trends across multiple scales, and the 60 mg dose achieved nominal significance on the key secondary endpoint (CGI-S-ADP, p=0.0077), supporting the Phase 3 strategy.
FDA granted Fast Track designation in July 2026, which can expedite development and review. Acadia has deep regulatory experience with the 5-HT2A mechanism through its approved drug Nuplazid.
Acadia's existing commercial infrastructure (Nuplazid and Daybue generated $342M in Q3 2026 revenue) means it can potentially commercialize remlifanserin without building a new sales force.
Analyst consensus remains bullish: 20 Buy/Strong Buy ratings vs 6 Hold and 1 Sell, with a mean price target of $30.53 (43.7% upside from the $21.23 close).
▼ Bear Case6
The Phase 2 primary endpoint narrowly missed statistical significance (p=0.0603 vs the 0.05 threshold), raising uncertainty about whether Phase 3 will succeed even with a refined design.
Acadia's prior attempt to expand Nuplazid (pimavanserin) into Alzheimer's disease psychosis failed in 2022 when the FDA rejected it for lack of evidence, suggesting the regulatory bar is high for this mechanism in ADP.
The Phase 3 program was amended after Phase 2 to drop the 30 mg arm and enrich for more severe patients, which could limit the addressable patient population if approved.
UBS downgraded ACAD from Buy to Neutral in October 2026 following the Phase 2 near-miss, and the CFO sold $69K in shares on October 30, 2026.
Phase 3 primary completion is not expected until January 2028, meaning no binary regulatory catalyst for over a year, and the stock could drift on pipeline uncertainty.
Several institutional investors trimmed or exited positions in Q2/Q3 2026, including First Trust (near-exit, -94.5%), Jane Street (near-exit, -85.9%), and Woodline Partners (full exit).

Upcoming Catalysts

  • Detailed Phase 2 RADIANT safety and efficacy data to be presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference, November 16-19, 2026 in Boston.
  • Phase 3 RADIANT program amendments and enrollment updates (ongoing).
  • Phase 2 Lewy body dementia psychosis trial data readout (timeline not yet disclosed).

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ACADIA PHARMACEUTICALS INC 8-K ACAD ·Originating report

Sources · 12

Hover a chip for the title
1 en.wikipedia.org2 acadia.com3 acadia.com4 psychiatrictimes.com5 psychiatrictimes.com6 cnspulse.com7 clinicaltrials.gov8 ir.acadia.com9 acadia.com10 alzforum.org11 insights.citeline.com12 mavenbio.com